Skip to main content

Table 2 Overall response rate to the treatment and polymorphisms observed

From: Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

Global distribution of polymorphisms (Pol) Response N (%) Stabilization or progression N (%) p value
VNTR
2R/2R 7 (77.8) 2 (22.2) 0.055
3R/3R 7 (100) 0 (0)
2R/3R 4 (50) 4 (50)
3R/4R 0 (0) 1 (100)
Pol VNTR (Subanalysis by EGFR status; group of native EGFR-patients)
2R/2R 7 (77.8) 2 (22.2) 0.017
3R/3R 7 (100) 0 (0)
2R/3R 2 (33.3) 4 (66.7)
3R/4R 0 (0) 1 (100)
Global distribution of SNP
Absence 6 (85.7) 1 (14.3) 0.626
Presence 12 (66.7) 6 (33.3)
Global distribution of polymorphisms in 3′-UTR
+6/+6 10 (83.3) 2 (16.7) 0.234
+6/-6 6 (54.5) 5 (45.5)
-6/-6 2 (100) 0 (0)
Pol 3′-UTR (Subanalysis by smoking habit stratification; group of active and former smokers)
+6/+6 8 (100) 0 (0) 0.085
+6/-6 4 (50) 4 (50)
-6/-6 2 (100) 0 (0)